Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Genscript Biotech ( (HK:1548) ) is now available.
Legend Biotech, an associate of Genscript Biotech, announced that CARVYKTI® generated approximately US$369 million in net trade sales for the quarter ended March 31, 2025. This announcement highlights the product’s strong market performance and its potential impact on the company’s financial health and industry standing.
More about Genscript Biotech
Genscript Biotech Corporation is a biotechnology company incorporated in the Cayman Islands, focusing on innovative biopharmaceutical products and services. Its associate, Legend Biotech, is listed on the Nasdaq Global Select Market in the U.S. and collaborates with Janssen Biotech, Inc. to develop and market CARVYKTI®, a pharmaceutical product.
YTD Price Performance: 2.36%
Average Trading Volume: 4,480
Technical Sentiment Signal: Buy
Current Market Cap: $2.95B
Find detailed analytics on 1548 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue